Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

Valneva Secures £20M From Scottish Enterprise For Vaccine Development

Valneva SE (NASDAQ:VALN) has been awarded research and development funding of up to £20 million by Scottish Enterprise.

  • The investment from Scotland's national economic development agency will comprise two grants and benefit the company's manufacturing site in Livingston. 
  • The company expects to receive grants over the next three years, commencing March 2022.
  • The first grant of up to £12.5 million will support research and development related to the manufacture of VLA2001, Valneva's inactivated, whole virus COVID-19 vaccine candidate. 
  • Related: Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial.
  • The second grant of up to £7.5 million will support research and development connected to Valneva's manufacturing processes for other vaccines.
  • Valneva's research and development portfolio include VLA1553, a single-shot vaccine candidate against the mosquito-borne viral infection chikungunya, which it intends to manufacture in Livingston. 
  • Related: Valneva Kickstarts Phase 3 Trial Of Chikungunya Vaccine Candidate In Adolescents.
  • Valneva reported 2021 revenues soaring 216% to €348.1 million.
  • Price Action: VALN shares closed at $33.61 on Friday.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.